The human growth hormone (hGH) plays a significant role in our bodies, influencing different processes from growth and organ development in our youth, to contributing to conditions like fibrosis, cancer, and diabetes in adulthood.
Understanding this, InfinixBio, in collaboration with Professor John Kopchick’s group at Ohio University, has embarked on pioneering research, which has now been prominently featured in a respected journal, the Journal of Biological Chemistry.
The highlight of this research is the introduction of a groundbreaking dual antagonist for both the human growth hormone and prolactin receptors.
This novel drug not only boasts an impressive long serum half-life, ensuring its prolonged presence in the bloodstream, but also remains effective in its main function, despite modifications made to achieve this longevity.
A key discovery of this research is the drug’s potent anti-cancer capabilities.
Initial tests with melanoma cancer cell lines show promising results: the drug effectively countered various growth-enhancing impacts of the growth hormone on tumor cells. Ongoing experiments indicate that this antagonist may have broader applications, showing efficacy against multiple types of cancer cell lines.
These findings are profound. With growth hormones known to stimulate tumor growth and support their resistance against drugs, this novel antagonist represents hope, especially for challenging cancer cases, like triple-negative breast cancer.
For those interested in delving deeper into this transformative research and understanding the methodologies, we invite you to explore the full article in the journal: Structure and Function of a Dual Antagonist of the Human Growth Hormone and Prolactin Receptors with Site-specific PEG Conjugates.
Our experienced lab team is here to help. Reach out today to learn more.
Back to Blog
